TITLE

FDA advisers recommend new controls on rosiglitazone use

AUTHOR(S)
Traynor, Kate
PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, p1306
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the recommendation of U.S. Food and Drug Administration (FDA) advisers to control or totally ban the rosiglitazone in patients suffering from type 2 diabetes mellitus. It states that some advisers at the meeting held in Gaithersburg, Maryland on July 13-14, 2010 advised the enhancement of the product's labeling to prevent ischemic cardiovascular risks and guarantee its safe use. It notes that Mark Woods of Saint Luke's Hospital favoured the product's removal in the market.
ACCESSION #
52946771

 

Related Articles

  • FDA Panel: Keep Avandia on Market With Restrictions. Young, Donna // BioWorld Today;7/15/2010, Vol. 21 Issue 135, p1 

    The article reports on the decision of a U.S. Food and Drug Administration (FDA) panel to restrict the use of the Type II diabetes drug Avandia (rosiglitazone) in the U.S. market. The panel also warned on possible heart attacks among patients taking the drug, which is manufactured by...

  • FDA committee urges tight restrictions on rosiglitazone. Roehr, Bob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/24/2010, Vol. 341 Issue 7765, p171 

    The article reports on the recommendation to prohibit the use of rosiglitazone drug in treating type 2 diabetes by the U.S. Food and Drug Administration's (FDA) advisory committee.

  • Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right? Krentz, Andrew; Hompesch, Marcus // Pharmaceutical Medicine - New Zealand;Jun2014, Vol. 28 Issue 3, p109 

    In 2008, the US Food and Drug Administration (FDA) issued guidance requiring demonstration of cardiovascular safety for all new glucose-lowering agents intended for the treatment of type 2 diabetes. The main driver for this move was the negative experience that the FDA had encountered with...

  • Cycloset Gets FDA Nod in Type II Diabetes.  // Bioworld Week;5/11/2009, Vol. 17 Issue 19, p5 

    The article reports on the U.S. Food and Drug Administration's approval of VeroScience LLC's lead product Cycloset. The drug would be the first dopamine agonist for treating Type II diabetes and the first drug approved by the FDA under the new cardiovascular safety guidelines. It indicates that...

  • FDA puts hold on rosiglitazone global post-marketing trial. Cohen, Deborah // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/31/2010, Vol. 341 Issue 7766, p222 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to suspend a post-marketing trial of thiazolidinedione rosiglitazone. FDA issued a partial clinical hold on a trial designed to compare the cardiovascular safety of rosiglitazone and pioglitazone in patients with...

  • Researcher urges Health Canada to suspend "unethical" diabetes drug trial. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;7/13/2010, Vol. 182 Issue 10, pE445 

    The article reports on the initiative of Canadian medical researchers which urge Health Canada to suspend the unethical trial for type 2 diabetes drug rosiglitazone. It relates that a safety alert has been issued by the U.S. Food and Drug Administration in 2007 concerning the possible...

  • Two new diabetes drugs on the market.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p35 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of two drugs indicated for the treatment of type 2 diabetes.

  • FDA restricts Rezulin use.  // Drug Store News;7/19/99, Vol. 21 Issue 11, pCP10 

    Reports the restriction made by the United States Food and Drug Administration (FDA) on the use of Warner-Lambert Co.'s Rezulin and revoked the drug's approval for use as monotherapy of patients with type II diabetes. Condition imposed by the FDA on Warner-Lambert concerning the use of the...

  • Colesevelam: A novel drug for comorbid diabetes and dyslipidemia. Dixit, Alok; Pandey, Pinki // Chronicles of Young Scientists;Oct-Dec2012, Vol. 3 Issue 4, p312 

    The article discusses the approval of the colesevelam hydrochloride by the U.S. Food and Drug Administration for type 2 diabetes mellitus and dyslipidemia. It mentions that the drug is approved as adjunctive treatment for T2DM in combination with sulfonylurea, metformin, and insulin therapy. It...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics